Abstract 14164: Intracoronary Compared with Intravenous Bolus Abciximab Application during Primary Percutaneous Coronary Intervention - 12 Month Follow-Up of the AIDA STEMI Trial

Background The AIDA STEMI trial compared i.c. versus i.v. abciximab bolus during primary PCI in ST-elevation myocardial infarction (STEMI) patients. At 90-day follow-up i.c. as compared to intravenous abciximab resulted in a similar 90-day rate of the primary composite clinical endpoint.1 However, there was a significant reduction in congestive heart failure. A longer follow-up is warranted. Here the 12-month data are reported. Methods and Results AIDA STEMI was a randomised, open-label, multicenter trial. Patients presenting with STEMI were randomly assigned in a 1:1 ratio to i.c. versus i.v. abciximab bolus during PCI with subsequent 12 h intravenous infusion. The primary efficacy endpoint was the composite of all-cause mortality, recurrent infarction or new congestive heart failure within 90 days. Secondary clinical endpoints were each individual component and included also a 12-month follow-up. Between July 2008 to April 2011, 2065 patients were assigned to intracoronary (n=1032) or intravenous abcixi...